Bris­tol My­ers pulls lym­phoma in­di­ca­tion for Is­to­dax af­ter con­fir­ma­to­ry tri­al falls flat

Amid an in­dus­try­wide re­view of can­cer drugs with ac­cel­er­at­ed ap­proval, Bris­tol My­ers Squibb had to make the tough call last month to yank an ap­proval for lead­ing I/O drug Op­di­vo af­ter flop­ping a con­fir­ma­to­ry study. Now, a sec­ond Bris­tol My­ers drug is on the chop­ping block.

Bris­tol My­ers has pulled ag­ing HDAC in­hibitor Is­to­dax’s in­di­ca­tion in pe­riph­er­al T cell lym­phoma af­ter a Phase III con­fir­ma­to­ry study for the drug flopped on its pro­gres­sion-free sur­vival end­point, the drug­mak­er said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.